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Background: World Health Organization (WHO) guidelines recommend for children with severe acute malnutrition
(SAM), high-dose vitamin A (VA) supplements be given on day 1 of admission, and on days 2 and 14 in the case of
clinical signs of vitamin A deficiency (VAD). Daily low-dose VA follows, delivered in a premix added to F-75 and F-
100. This study aimed to systematically review the evidence for safety and effectiveness of high-dose VA
supplementation (VAS) in treatment of children with SAM.
Methods: A comprehensive literature review was undertaken for all relevant randomized controlled trials (RCT) and
observational studies from 1950 to 2012. Studies identified for full review were evaluated using the Grading of
Recommendations, Assessment, Development and Evaluation (GRADE) methodology using a set of pre-defined
criteria: indirectness; inconsistency; imprecision; and study limitations. A quality rating of high, moderate, or low was
then assigned to each study, and only those attaining moderate to high were considered in making
recommendations.
Results: Of the 2072 abstracts screened, 38 met criteria for full review, and 20 were rated moderate to high quality.
Only one study replicated the WHO VA protocol in children with SAM. Indirectness was a critical limitation, as
studies were not exclusive to children with SAM. There was inconsistency across trials for definitions of malnutrition,
morbidities, and ages studied; and imprecision arising from sub-group analyses and small sample sizes. Evidence
showed improved outcomes associated with low-dose compared to high-dose VAS, except in cases presenting
with signs of VAD, measles, and severe diarrhea or shigellosis. Adverse outcomes related to respiratory infection,
diarrhea, and growth were associated with high-dose VAS in children who were predominantly adequately
nourished. No adverse effects of the high dose were found in children with SAM in the trial that replicated the
WHO VA guideline.
Conclusion: This is the first systematic review of the safety and efficacy of high-dose VAS in treatment of SAM. We
recommend a low-dose VAS regimen for children with SAM, except in cases presenting with measles, severe
diarrhea (shigellosis), and any indication of VAD. Further research is needed in exclusively malnourished children
and to explore alternate delivery strategies.
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Globally, vitamin A deficiency (VAD) affects 100–140
million children, 4.4 million of whom have xerophthal-
mia [1,2]. Coverage rates for full vitamin A supplemen-
tation (VAS) of children 6–59 months delivered through
primary care have risen significantly over the last decade,
reaching 88% for the least developed countries [3]. In re-
cent years, alternative strategies to improve micronu-
trient nutrition have been increasingly applied for high-
risk populations already supplemented with vitamin
A (VA): micronutrient powders; fortification of staple
foods; ready-to-use supplemental and therapeutic foods
(RUSF and RUTF); and other food-based approaches.
Among the populations particularly vulnerable to VAD
are children with severe acute malnutrition (SAM) [4].
The World Health Organization (WHO) currently rec-
ommends that for inpatient care of children with SAM,
VA supplements be given on day 1 of admission unless
there is clear evidence that VA was received in the last
month [5]. Dosing guidelines are the following: 200,000
international units (IU) for children over 12 months of
age, 100,000 IU for children 6–12 months, and
50,000 IU for children below 6 months. If clinical signs
of vitamin A deficiency are present, then another age-
specific, large dose is administered on day 2 and again,
on day 14 [4,5]. Low-dose VA is then given as part of a
vitamin mix added to F-75 or F-100 therapeutic milk
formulations, or alternatively, as a proprietary multivita-
min supplement or combined mineral-vitamin mix
(CMV). There is a need to revisit these guidelines in the
context of improved VA availability, but also in view of
evidence showing the potential for harmful effects of
such VAS dosages [6].
Methods
This systematic review aimed to assess the safety and
effectiveness of VAS in children with SAM, with
regards to mortality, nutritional recovery, and signs of
symptomatic VAD [7]. A literature review was under-
taken to search for all randomized controlled trials
(RCT) and observational studies published from 1950 to
March 2012. Databases searched included MEDLINE,
EMBASE, and Google Scholar. The clinical trial regis-
tries at clinicaltrials.gov, pactr.org, and apps.who.int/
trialsearch were also searched. Initial key words for the
searches included “malnutrition”, “severe malnutrition”,
“kwashiorkor”, “marasmus”, “vitamin A”, and “retinol”. A
number of outcome measures were sought, including
mortality, weight gain, nutritional recovery, and VAD.
Further terms were added iteratively to the search based
on results obtained from the initial searches.
Searches were also conducted to identify relevant pub-
lications and study documents produced by international
health organizations such as the WHO and UNICEF.The titles and abstracts were scanned to identify relevant
studies. The full text of relevant studies was obtained
and the list of articles for inclusion further optimized
based on an evaluation of the full text. Reference lists in
relevant articles were also scanned manually and elec-
tronically to identify other studies that may have been
missed in the original searches. Relevant publications
that cited those previously identified articles were simi-
larly sought.
Studies were included for full review based on
relevance to the population of interest, study inter-
ventions, study design, outcome measures, and an
assessment of the study’s methodological rigor and
quality. These studies were then assessed and en-
tered into a Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) table
summarizing design, aim, outcomes, GRADE criteria
assessment (indirectness, inconsistency, impreci-
sion, and study limitations), and quality ranking
(high, moderate, or low) [8].
Indirectness was judged based on study relevance to
the review question in terms of the study population
(children with SAM), intervention of interest (VAS), and
outcome measures (mortality, recovery from SAM, signs
of symptomatic VAD, and adverse outcomes due to sup-
plementation) [9]. Consideration was given under this
category to VA dosing relative the WHO protocol. In-
consistency was assessed by comparing point estimates
and examining the heterogeneity of methods and statis-
tical analyses [10]. Imprecision was based primarily on
the 95% confidence interval with consideration of effect
and sample sizes [11]. Potential biases (selection, recall,
information/observation, misclassification) arising from
failure to blind, losses in follow-up, inappropriate con-
trols, and failure to adjust for confounding factors,
among other problems, were considered under the study
limitations (risk of bias) criteria [12].
Once these criteria were assessed, each study
was assigned a quality ranking ranging from low to
high. Only those studies with some degree of moder-
ate or high (i.e., low-moderate, moderate, moderate-
high, or high) quality ranking were included in this
review for consideration in making recommendations
on the use of VAS for the treatment of children with
SAM.Results
Of the 2072 abstracts identified and screened, 38 were
selected for full review (Figure 1). Twenty-two were of
moderate- to high-quality, and were grouped into 3 cat-
egories and listed primary outcomes assessed: 1) previ-
ous reviews; 2) observational studies; and 3) randomized
controlled trials (RCT).
2073 records screened 
after duplicates removed
2035 records excluded 







- Serum/plasma retinol & SAM (n=4)






- Vitamin A status (n=0)
Figure 1 Flow diagram for studies included in review. The figure presents a flow diagram detailing the number of records screened and
excluded, full-text articles reviewed, and ultimately, the number of studies included in the systematic review. The included observational and RCT
studies are enumerated according to the primary outcome examined.
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Two previous reviews of VAS trials were identified; both
considered malnourished children together with those
not malnourished [7,13]. Preventive VAS reduced all-
cause mortality by 25% and diarrhea-specific mortality
by 30%. VA showed greater protection against morbidity
and mortality in Asia than in Africa or Latin America
[13]. An earlier review found that the severity of measles
and diarrheal infections were reduced by VAS, but the
risk of lower respiratory tract infection was increased in
some trials [7]. Because the reviews did not provide new
evidence for VA and management of SAM and all stud-
ies from the reviews were screened for this review, they
were not included in the GRADE assessment.
Observational studies
Five observational studies were identified and assigned a
GRADE quality ranking of low to moderate [14-18]
(Additional file 1: Table S1). These studies found signifi-
cant associations between serum or plasma retinol con-
centrations and SAM [14-16]. Others established a link
between VAD, SAM, and diarrhea. In Bangladesh, re-
duced serum retinol concentrations were associated with
shigellosis and low weight-for-age Z-score [18]. Another
case–control study in Bangladesh showed that the dur-
ation of diarrhea and SAM were independently associ-
ated with xerophthalmia [17].
Randomized controlled trials
Fifteen RCTs of moderate to high quality based on
GRADE criteria were included in the systematic review
on the safety and efficacy of high-dose VAS in children
with SAM (Table 1). Issues of indirectness were presentin all trials. Only one trial included children with SAM
exclusively [19]. The remaining 14 included non-
malnourished and malnourished children [20-33]. VA
dosing also varied; only five trials administered the
recommended high-dose on day 1 [19,26,30,31,33], while
the remaining administered VA doses in varying quan-
tities and forms. Only one trial followed the WHO
protocol [19]; two compared high dose with daily low
dose [26,33], and the remaining 12 compared high dose
VAS with placebo [20-25,27-32].
Inconsistency across trials was observed with regards
to the ages of children studied, ranging from birth to
14 years. Definitions of morbidity and malnutrition var-
ied, as well as use of differing growth references and
standards. Small sample sizes and rare events were the
most common problems related to imprecision. Despite
randomization, several studies also showed significant
differences in baseline characteristics that elevated the
risk of bias. Notably, these included baseline age and nu-
tritional status differences with higher likelihoods of
confounding [28,32,33].
Some key findings were identified across trials. First,
low-dose VAS conferred more or similar health and re-
covery advantages when compared to high-dose supple-
mentation in the treatment of malnourished children
[19,26,33]. Second, high-dose VAS showed mixed results
relative to placebo for infectious disease outcomes in
children with and without SAM, showing benefit in
some trials for children with severe diarrhea or shigello-
sis [27,31], measles [21,22], other acute respiratory infec-
tions [30], and undifferentiated fever [24]. However, in
other trials, there was no benefit for children with acute
respiratory infections or diarrhea [24-26,29,32]. There
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Table 1 Randomized controlled trials included in the systematic review (Continued)
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Table 1 Randomized controlled trials included in the systematic review (Continued)
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Table 1 Randomized controlled trials included in the systematic review (Continued)
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associated with high-dose VAS among VA deficient chil-
dren [20] and children with measles [22].
Finally, adverse effects were found to be associated
with high-dose VAS in some trials, including an in-
creased rate of respiratory illnesses [23,28] and diarrhea
[26,31]. These findings appear primarily in samples or
sub-samples of adequately nourished children. As noted
previously, we identified only one RCT that included
only severely malnourished children [19]. Some explicitly
excluded children with marasmus, kwashiorkor, or all
children with SAM [25,27,30,32], while the remaining
included both malnourished and adequately nourished
children. Among the five studies finding adverse events
in association with VAS, two of these studies carried out
sub-group analyses showing an increased risk of diarrhea
among normally nourished children [31] and among
children without edema [26]. One trial included only ad-
equately nourished children [28], another found in-
creased risk of ALRI in mainly adequately nourished
children [23], and one included both malnourished and
adequately nourished children, excluding children with
SAM [32]. No adverse effects of the high-dose VAS were
found in children with SAM in the trial that replicated
the WHO VA guidelines [19].
Discussion
Our systematic review of the literature using the
GRADE methodology revealed only limited evidence
that directly addresses the safety and effectiveness of
high-dose VAS for children with SAM. Fourteen of the
15 RCTs identified for this review included both mal-
nourished and non-malnourished children, thereby com-
plicating the extrapolation of findings directly to efficacy
and safety of VAS for SAM. There is sufficient evidence
to recommend the use of high-dose VAS for children
with SAM when presenting with measles, severe diar-
rhea (shigellosis), or evidence of VAD. The low-dose
VAS regimen should be considered as the preferred
protocol in other cases of malnourished children, given
the potential for adverse events and similar recovery
outcomes when compared to high-dose VAS. Higher
quality prospective studies are still needed to directly
examine VAD in children with SAM, applying more con-
temporary definitions of morbidity and malnutrition,
and powered sufficiently to detect the critical outcomes
of interest.
Observational studies demonstrated an association be-
tween SAM and VAD, but metabolic disruptions in
SAM might preclude accurate measures of true VA sta-
tus. Blood biomarkers of retinol concentrations were pri-
marily used to indicate VA status [14-16,18]. Protein-
energy malnutrition has been associated with reduced
hepatic synthesis of retinol binding protein (RBP) andtransthyretin used to transport VA in the body [34,35].
Thus, VA stores in the liver may not be mobilized ap-
propriately in malnourished children and therefore not
be reflected in blood biomarkers. Mitra showed that VA
status improved from baseline to hospital discharge,
even without VAS [18]. That study also showed that
while urinary losses of retinol were associated with low
retinol concentrations in children with dysentery, other
inflammatory markers such as body temperature and
serum α-1-acid glycoprotein and C reactive protein con-
centrations were more highly and negatively correlated
with vitamin A status.
There is some evidence that diarrhea could be mediat-
ing this relationship, as revealed by independent associa-
tions between diarrhea, low WAZ, and VA levels [17].
Shigellosis, in particular, increases the risk of VAD [18].
A study in Brazil showed a possible interaction between
SAM and low serum retinol concentrations for higher
diarrheal morbidities [15]. Evidence from RCTs also
finds that high-dose VAS may be beneficial for treating
severely malnourished children in cases of severe diar-
rhea [27,31]. Again, the mechanism by which VA may be
operating to mitigate severe diarrhea in SAM has not
been elucidated, but it may be either through the repair
of the gut epithelium or immune pathways that restore
balance between T-cell subsets [36].
Two studies showed unequivocally the benefit of lose-
dose (5000 IU daily until discharge) compared to a sin-
gle high-dose (200,000 IU for children over 12 months
or 100,000 IU for children under 12 months on day 1 of
hospitalization) VAS regimen [26,33]. The low-dose regi-
men was more strongly correlated with lower incidence
and shorter duration of respiratory disease [33] and a
lower incidence of severe diarrhea [26]. A third study in
Bangladesh also examined the administration of a lose-
dose protocol in relation to a high-dose on day 1
followed by daily low doses until hospital discharge. [19].
That study did not find any differences in the two
groups on a range of morbidity and nutrition recovery
outcomes and adverse events. All children at baseline
had diarrhea and while clinical signs of VAD were not
apparent, baseline measures of VA status did indicate
VAD in the sample. With regards to other morbidities,
high-dose VAS was effective in reducing measles-specific
respiratory illness [21,22], but showed mixed results with
regards to non-measles pneumonia and other acute
lower respiratory tract infections in children with SAM
[23-25,28-30,32,37,38].
Only one trial identified in this review specifically
included children who were HIV + [31]. Sub-group ana-
lyses stratified by HIV status showed a trend towards
a protective effect of high-dose VAS on cough and
rapid respiratory rate for HIV-infected children [RR
0.54 (0.24-1.20), p = 0.07], while children without HIV
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1.47 (1.16-1.86), p = 0.001]. Because children infected
with HIV are highly vulnerable to SAM and VAD, more
research is needed to understand the optimal protocols
for this population [39].
The evidence for growth outcomes in the follow-up
period from hospital discharge was limited and some-
what dated [20,22]. One study showed that only among
children who were VA deficient at baseline were there
greater improvements in weight and MUAC in those
who received high-dose VAS; this was not evident in the
non-VA deficient children and high-dose VAS even re-
duced height gain among non-VA deficient girls [20].
Standard therapeutic foods designed for growth recovery
in SAM may be a safer source of VA in certain cases.
The foods contain VA as retinyl acetate, similar to
VA supplements, in the following concentrations (per
100 g): F-75, 900 μg; F-100, 800 μg; and RUTF, 800–
1100 μg. Thus, for a child weighing 5 kg, this would
translate into 1,119 μg/d VA for F-75, or 1,544 μg/d VA
for F-100, and 1,680 μg/d VA for RUTF. These quan-
tities are comparable to the low-dose regimen of
5000 IU or 1500 μg retinol and are well below the high-
dose recommendation of 100,000 IU or 30,000 μg/d VA
that would be given to children under 12 mo. While
these foods have not specifically been assessed as alter-
natives to VAS, the safety and efficacy of these products
in the treatment of SAM is well-accepted [40-42]. Par-
ticularly in cases when a child’s VA status is unknown or
adequate, therapeutic foods could thus serve as the de-
livery mechanism for low-dose VAS, though more re-
search is needed.
Adverse effects found to be associated with high-dose
VAS warrant more research. The most frequent negative
outcome was an increased risk of acute respiratory infec-
tions [23,28,31,33]. There was also evidence of an in-
creased risk of acute, non-severe diarrhea, mediated in
part by nutritional status [26,31,32]. It should be noted
that the adverse effects arising from high-dose VAS were
found in samples or sub-samples that included primarily
adequately nourished children. Heterogeneity in baseline
characteristics and study design complicates compari-
sons across the various studies, but these safety issues
should not be ignored. Excessive intake of preformed
VA, notably in the absence of dietary fatty acids, may
overwhelm the esterification process and introduce more
harmful forms of VA into the child’s circulation [6]. Fur-
ther along the metabolic pathway, VA presented to cell
membranes in forms other than the RBP complex (as
may be the case in SAM) can also lead to significant cel-
lular damage [43]. Carotenoid forms of VA or lipid-
based nutrient supplements such as RUTF, should be ex-
plored to minimize oxidative stress while still addressing
VAD [44].Conclusions
In the treatment of children with SAM, a high-dose VAS
protocol can be safely recommended in cases presenting
with measles, severe diarrhea (shigellosis), or symptoms
of VAD. More research is needed to study this specific
question in populations exclusively malnourished and to
understand and prevent adverse outcomes related to
high-dose VAS. We recommend exploration of alterna-
tive low-dose protocols and strategies beyond VAS, such
as use of carotenoids or RUTF interventions, to address
VA deficiency and associated health outcomes in the
treatment of children with SAM.
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